Status:
COMPLETED
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
Lead Sponsor:
Grupo Hospital de Madrid
Conditions:
Progression Free Survival
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Treatment options for patients with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to ...
Eligibility Criteria
Inclusion
- Colorectal adenocarcinoma stage IV patients.
- ECOG= 0-1
- Age \> 18 years.
- Fit to receive chemotherapy treatment
- Availability of tumor tissue or possibility of a tumor biopsy to determine therapeutic targets.
- Adequate renal (Cr \< 1,5 mg/d), liver (bilirubin≤1,5 mg/dl, AST and ALT ≤ 3.0 x the upper limit of normal) and normal bone marrow function ( absolute neutrophil count ≥ 1500/µl, hemoglobin ≥ 9.0g/dl and a platelet count of ≥ 100.000/µl)
Exclusion
- Contraindication for the administration of any of the drugs used in the study including capecitabine, irinotecan, oxaliplatin, cetuximab or bevacizumab.
- Previous Chemotherapy treatment
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT01453257
Start Date
October 1 2009
End Date
October 1 2011
Last Update
October 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Integral Oncológico Clara campal
Madrid, Madrid, Spain, 28050